Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
Received: 28 August 2017
Accepted: 27 July 2018
First Online: 3 August 2018
Ethics approval and consent to participate
: The study protocol was approved by the Ethics Committee of Peking University People’s Hospital and the study is registered in the Chinese Clinical Trial Registry (ExternalRef removed) as # ChiCTR-OCH-11001699. Informed consent was obtained from each patient before screening for both treatment and evaluation of HRQoL.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.